Pipeline news

• Epic Sciences Unveils Definembc™, a Novel Blood-Based Test Designed to Improve Care for Metastatic Breast Cancer Patients

  16 December 2021

  

  Epic Sciences, Inc. announces DefineMBC, a novel metastatic breast cancer (MBC) test that includes both cell-based and cell-free analysis from a single blood draw. DefineMBC provides comprehensive MBC profiling when a tissue biopsy result is not available.

• Epic Sciences Platform Demonstrates Compelling Value of Cell Analysis in Data Presented at San Antonio Breast Cancer Symposium 2021

  15 December 2021

  

  Epic Sciences, Inc. (Epic)’s comprehensive liquid-biopsy platform continues to deliver compelling cancer profiling information as data presented during the San Antonio Breast Cancer Symposium 2021 demonstrate.

• binx health Selected as a Top Digital Health Startup that is Transforming the Future of Healthcare -- Named to the 2021 CB Insights Digital Health 150 List

  15 December 2021

  

  binx health, a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study, and shop, announced today that CB Insights ranked binx health among the most promising digital health startups in the world.

• Epic Sciences Expands Leadership Team to Address Liquid Biopsy Demand

  15 December 2021

  

  Epic Sciences, Inc., developer of novel diagnostics to personalize and advance the treatment and management of cancer, today announced the appointment of Jason Christiansen as Chief Technology Officer, Mark Aguillard as Vice President/ General Manager of the Oncology Business Unit, and Amara Siva as Vice President of Laboratory Operations. These three new executives bring a combined 60 plus years of experience to the Epic Sciences team.

• binx health and Student Health Insurer, Wellfleet, Expand Agreement in College Health for In-Dorm and At-Home Access to Testing for Sexually Transmitted Infections (STIs)

  09 December 2021

  

  With STIs on the rise, Wellfleet takes leadership role in offering its college partners convenient, accurate, and discreet at-home solutions for sexual health.

• Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting

  03 December 2021

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced new clinical trial and research data being presented at the American Epilepsy Society (AES) Annual Meeting in Chicago, Illinois, including new quality of life and extended safety and efficacy data of ganaxolone in CDKL5 deficiency disorder (CDD) and a quantitative EEG analysis and case reports of patients in super-refractory status epilepticus.

• Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results

  09 November 2021

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided an update on its clinical and regulatory development activities and reported its financial results for the third quarter ended September 30, 2021.

• Marinus Pharmaceuticals Joins the Loulou Foundation in Collaboration on CANDID, a Comprehensive Observational Study in CDKL5 Deficiency Disorder

  26 October 2021

  

  Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced it has joined forces with the Loulou Foundation, a private foundation dedicated to advancing research on the causes and treatment of CDKL5 deficiency disorder (CDD), and six other biotech and pharmaceutical organizations, to undertake a key observational CDD clinical study to better understand the natural history and the utility of various clinical assessments. Marinus and the other industry organizations will share in the funding and governance of a three-year observational study in CDD patients – the Clinical Assessment of NeuroDevelopmental measures In CDD (CANDID) study. 

• Cothera Bioscience Acquires Zotiraciclib from Adastra Pharmaceuticals

  06 October 2021

  

  Cothera Bioscience Inc. and Adastra Pharmaceuticals Inc., private biopharmaceutical companies focused on the development of first-in-class therapeutics for the treatment of cancer, today announced a definitive agreement under which Cothera has acquired zotiraciclib (ZTR), an oral kinase inhibitor that readily crosses the blood brain barrier and possesses a unique mechanism of action of Myc depletion via the inhibition of cyclin-dependent kinase 9 (CDK9). Financial terms of the asset purchase were not disclosed.

• Marinus Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in CDKL5 Deficiency Disorder

  20 September 2021

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the U.S. Food and Drug Administration (FDA) accepted for filing the company’s New Drug Application (NDA) for the use of ganaxolone in the treatment of seizures associated with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy.